Pacira BioSciences (PCRX) Stock: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$36.39
11.19 (44.40%)
▲
5d:
+45.5%
30d:
+40.61%
90d:
+42.82%
WAIT
LOW Confidence
Analysis Updated: Oct 8, 2026 12:00 AM ET
Earnings: Nov 05, 2026
26d
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: PCRX is 30.7% above its trading range ($27.84). Market expects 15.5% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: PCRX is 30.7% above its trading range ($27.84). Market expects 15.5% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$40.81
Based on 11.8% avg growth
INTRINSIC VALUE TODAY
$25.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $36.39, which is considered extended relative to its 30-day fair value range of $23.50 to $27.84. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.5) compared to its historical average (6.8). At these levels, the market is pricing in 15.5% annual earnings growth.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $36.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 44.4% recently.
Market Sentiment: PCRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $30.11. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $36.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 44.4% recently.
Market Sentiment: PCRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $30.11. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$23.50 -
$27.84
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
17.6%
All Signals
- BEARISH: Price significantly overextended (+30.7% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+44.4%)
- BEARISH: Trading 17.3% above Wall St target ($30.11)
- BULLISH: Expecting earnings turnaround to 15.5% growth with 6.2% revenue growth
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$23.50 -
$27.84
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$24.56
Resistance Level
$36.46
Current Trend
Uptrend
Technical data as of
Oct 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.50
Wall Street Target
$30.11
(-17.3%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
-30.0%
Profit Margin
2.0%
Valuation Premium vs History
+15.5% premium
PE vs Historical
10.5 vs 6.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.5%
(market-implied from PE analysis)
1-Year Target
$42.03
(+16%)
2-Year Target
$48.55
(+33%)
3-Year Target
$56.07
(+54%)
3-Yr Target (if PE normalizes)
(PE: 11→7)
PE COMPRESSION
$36.30
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.7, Growth: 19.5%)
$116.45
(+220%)
Base:
(SPY PE: 10.5, Growth: 19.5%)
$62.09
(+71%)
Bear:
(PE: 6.8, Growth: 19.5%)
$40.20
(+11%)
📈
Valuation based on Current Earnings
Forward PE: 6.25 | Forward EPS (Implied): $5.82
Bull Case
$43.94
(+21%)
Analyst growth 15.0%, PE expands to 6.6
Base Case
$36.39
(0%)
Market implied 0.0%, PE stable at 6.3
Bear Case
$27.84
(-24%)
Severe decline -15.0%, PE contracts to 5.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 08, 2026 8:36 PM ET
Data refreshes hourly during market hours. Next update: 9:36 PM
Data refreshes hourly during market hours. Next update: 9:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Shawn Cross
SELL
12941 shares
2026-04-23
Shawn Cross
SELL
1500 shares
2026-04-22
Shawn Cross
SELL
2845 shares
2026-04-21
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
28 analysts |
$208 | 54 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 58 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 57 HOLD |
|
KNSA
Kiniksa Pharmaceuticals … |
STRONG BUY
8 analysts |
$98 | 69 BUY |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 56 HOLD |
